COMPREHENSIVE ANALYTICAL EVALUATION OF THE INTERRELATIONSHIPS BETWEEN THE FGF-23/α-KLOTHO SYSTEM, MINERAL METABOLISM BIOMARKERS, AND BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN
Keywords:
FGF-23; α-Klotho; postmenopausal women; osteoporosis; bone mineral density; calcium; phosphate; vitamin D; PTH; mineral metabolism.Abstract
Postmenopausal osteoporosis is a major metabolic bone disorder characterized by progressive reduction in bone mineral density (BMD) and increased fracture risk. Although estrogen deficiency is considered a central determinant of postmenopausal bone loss, increasing evidence indicates that systemic regulators of mineral metabolism may also influence skeletal health. Fibroblast growth factor 23 (FGF-23) and α-Klotho constitute an important endocrine signaling system involved in phosphate homeostasis, vitamin D metabolism, and bone-mineral regulation. FGF-23, predominantly produced by osteocytes and osteoblast-lineage cells, reduces renal phosphate reabsorption and suppresses renal production of 1,25-dihydroxyvitamin D. α-Klotho acts as an essential co-receptor for canonical FGF-23 signaling, particularly in the kidney. The interaction between FGF-23, α-Klotho, parathyroid hormone (PTH), calcium, phosphate, and vitamin D forms a complex regulatory network rather than an isolated hormonal pathway. Existing studies investigating the relationship between FGF-23, α-Klotho, and BMD in postmenopausal women have produced heterogeneous findings. Some studies have reported higher FGF-23 concentrations in women with osteoporosis, whereas others have found no independent association between FGF-23 and BMD. In contrast, several studies suggest that higher circulating α-Klotho concentrations may be associated with greater BMD and a lower probability of osteoporosis. These discrepancies may be explained by differences in renal function, age, vitamin D status, assay methodology, menopausal duration, body composition, and other confounding factors. This review summarizes current evidence concerning the FGF-23/α-Klotho system, mineral metabolism biomarkers, and BMD in postmenopausal women and proposes a comprehensive biomarker and statistical framework for future clinical research.
References
1. Celik E, Guzel S, Abali R, Guzelant AY, Celik Guzel E, Kuçukyalcin V. The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women. Minerva Med. 2013;104(5):497–504.
2. Determination of fibroblast growth factor 23. Ann Clin Biochem. 2009. doi:10.1258/acb.2009.009066.
3. Erben RG. Update on FGF23 and Klotho signaling. Mol Cell Endocrinol. 2016;432:56–65. doi:10.1016/j.mce.2016.05.008.
4. Erben RG, Andrukhova O. FGF23-Klotho signaling axis in the kidney. Bone. 2017;100:62–68. doi:10.1016/j.bone.2016.09.010.
5. Fauconnier C, Roy T, Gillerot G, Roy C, Pouleur AC, Gruson D. FGF23: Clinical usefulness and analytical evolution. Clin Biochem. 2019. doi:10.1016/j.clinbiochem.2019.03.002.
6. Fukumoto S. FGF23/Klotho and bone metabolism. Clin Calcium. 2009;19(7):945–950.
7. Han W, Bai XJ, Han LL, Sun XF, Chen XM. The relationship between serum fibroblast growth factor 23, Klotho, and lumbar spine bone mineral density in northern Chinese postmenopausal women. Menopause. 2019;26(5):546–553. doi:10.1097/GME.0000000000001276.
8. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013;75:503–533. doi:10.1146/annurev-physiol-030212-183727.
[11.09.2026 11:06]
9. International Society for Clinical Densitometry. 2023 ISCD Official Positions—Adult. ISCD Official Positions. 2023.
10. Jiang J, Liu Q, Mao Y, Wang N, Lin W, Li L, et al. Klotho reduces the risk of osteoporosis in postmenopausal women: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES). BMC Endocr Disord. 2023;23:151. doi:10.1186/s12902-023-01380-9.
11. Kato S. Hormones and osteoporosis update. Estrogen and bone remodeling. Clin Calcium. 2009;19(7):951–956.
12. Kuro-o M. Klotho as a regulator of oxidative stress and aging. Biol Chem. 2008;389(3):233–241.
13. Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009;1790(10):1049–1058.
14. Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dent Res. 2006;85(7):584–595. doi:10.1177/154405910608500703.
15. McNamara LM. Osteocytes and estrogen deficiency. Curr Osteoporos Rep. 2022. doi:10.1007/s11914-021-00702-x.
16. Portales-Castillo I, Simic P. PTH, FGF-23, Klotho and Vitamin D as regulators of calcium and phosphorus: genetics, epigenetics and beyond. Front Endocrinol (Lausanne). 2022;13:992666. doi:10.3389/fendo.2022.992666.
17. Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. 2009;5:611–619.
18. Shen J, Fu S, Song Y. Relationship of Fibroblast Growth Factor 23 (FGF-23) Serum Levels With Low Bone Mass in Postmenopausal Women. J Cell Biochem. 2017;118(12):4454–4459. doi:10.1002/jcb.26101.
19. Sirikul W, Siri-Angkul N, Chattipakorn N, Chattipakorn SC. Fibroblast Growth Factor 23 and Osteoporosis: Evidence from Bench to Bedside. Int J Mol Sci. 2022;23(5):2500. doi:10.3390/ijms23052500.
20. Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporos Int. 2016. doi:10.1007/s00198-016-3543-5.
21. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774.
